HGEN - Humanigen stock gains as lenzilumab nabs expedited rolling review in U.K. for COVID-19

Humanigen (HGEN) perks up 5% premarket after U.K.'s Medicines and Healthcare Products Regulatory Agency ((MHRA)) accepted its submission for Marketing Authorization of lenzilumab in COVID-19 for expedited rolling review, with assessment expected to occur more rapidly than a standard rolling review. “We continue to work with our partners to prepare for distribution of lenzilumab pending conditional approval of its use to treat hospitalized patients with COVID-19,” noted Timothy E. Morris, COO and CFO of Humanigen.“In the event Emergency Use Authorization in the United States and Marketing Authorization in the UK are awarded concurrently or in parallel, we will work with the relevant authorities to ensure appropriate allocation of lenzilumab in each country.”

For further details see:

Humanigen stock gains as lenzilumab nabs expedited rolling review in U.K. for COVID-19